PHR 957 Final Exam Study Set
What is the typical Tx for NSCLC Stage I with a tumor <4cm? - ANSWER Just surgery
and monitoring
What is the typical Tx for NSCLC Stage I-IIIa? - ANSWER Surgery with Adjuvant or
Neoadjuvant Therapy
-EGFR WT: Platinum doublet, Atezolizumab x 16 cycles
-EGFR Mutation: +/- Platinum doublet, Osimertinib x 3 years
What is the typical Tx for NSCLC Stage IIIb? - ANSWER Chemoradiation - Durvalumab
consolidation
What is the typical Tx for NSCLC stage IV? - ANSWER -Systemic Therapy:
surgery/radiation for palliation
-Precision medicine for targetable driver mutation
-Chemoimmunotherapy: PD-L1 expression < 50%
-(TPS)Immunotherapy: PD-L1 > 50% (TPS)
In NSCLC what PD-L1 percentage do you consider Immunotherapy as opposed to
chemotherapy? - ANSWER -Immunotherapy: PD-L1 >49%
-Chemotherapy: PD-L1 <50%
What are the immunotherapy and chemotherapy options for metastatic NSCLC? -
ANSWER Immunotherapy: PD-L1 >49%
-Pembrolizumab
-Atezolizumab
-Cemiplimab
-Nivolumab/ipilimumab
--May add on chemotherapy
Chemotherapy: PD-L1 <50%
-Non-Squamous
--Platinum/pemetrexed/pembrolizumab Carboplatin/paclitaxel/bevacizumab/
atezolizumab
, --Carboplatin/alb bound paclitaxel/atezolizumab
--Platinum/pemetrexed/nivolumab/ipilimumab
-Squamous
--Carboplatin/paclitaxel*/pembrolizumab
--Carboplatin/paclitaxel/nivolumab/ipilimumab
For a patient with prostate cancer what is the Tx for Regional Lymph Node Positive
Non-Metastatic Disease (ADT naïve) that someone had had for less than 5 years and
asymptomatic? - ANSWER Observation or ADT
For a patient with prostate cancer what is the Tx for Regional Lymph Node Positive
Non-Metastatic Disease (ADT naïve) that someone had had for more than 5 years or
symptomatic? - ANSWER Radiation + ADT ± abiraterone or ADT ±abiraterone or Surgery
+ Radiation + ADT
For PSADT ≤ 10 mo what are the preferred regimens? - ANSWER -ADT + Apalutamide
-ADT + Darolutamide
-ADT + Enzalutamide
For the treatment of Metastatic CNPC (ADT naïve) what are the preferred regimen? -
ANSWER -ADT + Docetaxel + Abiraterone (preferred for patients with highvolume
disease)
-ADT + Docetaxel + Darolutamide (preferred for patients with high volume disease)
-ADT + Apalutamide
-ADT + Enzalutamide
-ADT + Abiraterone
What is the preferred treatment for Metastatic CRPC - ANSWER All patients should
receive ADT
-Preferred regimens
--Docetaxel (preferred for high volume disease)
--Enzalutamide
--Abiraterone
For cancer induced Skeletal Related Events (SRE's) what can be given as prevention? -
ANSWER -Bisphosphonates
-RANKL inhibition
What is the typical Tx for NSCLC Stage I with a tumor <4cm? - ANSWER Just surgery
and monitoring
What is the typical Tx for NSCLC Stage I-IIIa? - ANSWER Surgery with Adjuvant or
Neoadjuvant Therapy
-EGFR WT: Platinum doublet, Atezolizumab x 16 cycles
-EGFR Mutation: +/- Platinum doublet, Osimertinib x 3 years
What is the typical Tx for NSCLC Stage IIIb? - ANSWER Chemoradiation - Durvalumab
consolidation
What is the typical Tx for NSCLC stage IV? - ANSWER -Systemic Therapy:
surgery/radiation for palliation
-Precision medicine for targetable driver mutation
-Chemoimmunotherapy: PD-L1 expression < 50%
-(TPS)Immunotherapy: PD-L1 > 50% (TPS)
In NSCLC what PD-L1 percentage do you consider Immunotherapy as opposed to
chemotherapy? - ANSWER -Immunotherapy: PD-L1 >49%
-Chemotherapy: PD-L1 <50%
What are the immunotherapy and chemotherapy options for metastatic NSCLC? -
ANSWER Immunotherapy: PD-L1 >49%
-Pembrolizumab
-Atezolizumab
-Cemiplimab
-Nivolumab/ipilimumab
--May add on chemotherapy
Chemotherapy: PD-L1 <50%
-Non-Squamous
--Platinum/pemetrexed/pembrolizumab Carboplatin/paclitaxel/bevacizumab/
atezolizumab
, --Carboplatin/alb bound paclitaxel/atezolizumab
--Platinum/pemetrexed/nivolumab/ipilimumab
-Squamous
--Carboplatin/paclitaxel*/pembrolizumab
--Carboplatin/paclitaxel/nivolumab/ipilimumab
For a patient with prostate cancer what is the Tx for Regional Lymph Node Positive
Non-Metastatic Disease (ADT naïve) that someone had had for less than 5 years and
asymptomatic? - ANSWER Observation or ADT
For a patient with prostate cancer what is the Tx for Regional Lymph Node Positive
Non-Metastatic Disease (ADT naïve) that someone had had for more than 5 years or
symptomatic? - ANSWER Radiation + ADT ± abiraterone or ADT ±abiraterone or Surgery
+ Radiation + ADT
For PSADT ≤ 10 mo what are the preferred regimens? - ANSWER -ADT + Apalutamide
-ADT + Darolutamide
-ADT + Enzalutamide
For the treatment of Metastatic CNPC (ADT naïve) what are the preferred regimen? -
ANSWER -ADT + Docetaxel + Abiraterone (preferred for patients with highvolume
disease)
-ADT + Docetaxel + Darolutamide (preferred for patients with high volume disease)
-ADT + Apalutamide
-ADT + Enzalutamide
-ADT + Abiraterone
What is the preferred treatment for Metastatic CRPC - ANSWER All patients should
receive ADT
-Preferred regimens
--Docetaxel (preferred for high volume disease)
--Enzalutamide
--Abiraterone
For cancer induced Skeletal Related Events (SRE's) what can be given as prevention? -
ANSWER -Bisphosphonates
-RANKL inhibition
